Clinical trial
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
NCT00427596 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00427596 |
|---|---|
| Title | A Two-Part Study to Determine: Best Medication Formulation and Food Effect |
| Official title | A Two-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Four MR Formulations and Food Effect of GW427353 (Solabegron) in Healthy Adult Subjects |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Overactive Bladder |
| Intervention type | Drug |
| Interventions | Solabegron |
| Enrollment | 18 |
| Start date | Jan 1, 2007 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jan 29, 2007 |
| Last update posted | Oct 7, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: